Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

124.16 +1.06 (+0.86%)
Streaming Delayed Price Updated: 11:43 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
46 47 Next >
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
Via Benzinga
Death Cross Looms Over Novartis Investors
If history is any guide, there may be trouble ahead for shares of Novartis (NYSE:NVS). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Mark Cuban Says Americans Shouldn't Have To Pick Between Rent, Food Or Medicine
Famed billionaire, entrepreneur and Dallas Maverick’s owner Mark Cuban thinks Americans shouldn’t have to pick between necessities such as food, medicine or rent. And he’s provided a solution for at... 
Via Benzinga
Amphetamine Drug Market 2022: Industry Analysis, Size, Global Trends, Share, Growth, Opportunity and Forecast to 2028
Amphetamine Drug Market SWOT Analysis Including Key Players Pfizer, Novartis, Eli Lilly, GSK, Hisamitsu Pharmaceutical, Purdue Pharma 
Via SBWire
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
Recap: Novartis Q2 Earnings
  Novartis (NYSE:NVS) reported its Q2 earnings results on Tuesday, July 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments. 
Via InvestorPlace
As Snap Spooks Market, Here Are The Hits & Misses Of Q2 Reporting Season
Snap, Inc. (NYSE: SNAP) was among the high-profile disappointment thus far in the second-quarter reporting season. 
Via Benzinga
Stock Market Rally Breaks Higher; Tesla, Netflix, Snap, United Airlines Key Earnings: Weekly Review
But a slew of earnings reports and another big Fed rate hike loom. 
Via Investor's Business Daily
New Indication Approval For Incyte "To Usher New Growth Avenue"
Via Benzinga
HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders
Via Benzinga
Ford, General Motors Rally; Check These Other Big Gainers From Yesterday
U.S. stocks closed sharply higher, with the Dow Jones gaining more than 750 points on Tuesday. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and... 
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Beats Second-Quarter Earnings Goal But Sales Light
Swiss drugmaker Novartis on Tuesday delivered better-than-expected earnings for the second quarter but sales were light. Novartis stock rose. 
Via Investor's Business Daily
IBM And 20 Stocks Moving Premarket
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) rose 32.1% to $1.40 in pre-market trading after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised... 
Via Benzinga
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
Via Benzinga
Earnings Preview For Novartis
Novartis (NYSE:NVS) is set to give its latest quarterly earnings report on Tuesday, 2022-07-19. Here's what investors need to know before the announcement. Analysts estimate that Novartis will report... 
Via Benzinga
Tesla, Twitter, Goldman Among Headline Earnings Of Unfolding Week: Here Are The Key Earnings Ahead
The June quarter reporting season is entering its second week, with the focus gradually shifting from banks to technology companies. 
Via Benzinga
Stock Market Overview For The Week Of July 18, 2022
This past week we got new red-hot CPI numbers, further drama in the Elon Musk and Twitter saga, and the start of earnings season. 
Via Talk Markets
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
The company just hired three new executives, likely putting a buyout in the rearview. 
Via Investor's Business Daily
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell... 
Via Benzinga
Global Liposarcoma Treatment Market 2022 Business Strategies and Overview Report 2031 Taro Pharmaceuticals, Sandoz, Pfizer, Eli Lilly, Sanofi SA, Novartis AG
The intelligent report on the global Liposarcoma Treatment market provides deep analysis of the Liposarcoma Treatment industry segments including product type, application, special geographies and... 
Via SBWire
Topics Supply Chain
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
Via Benzinga
Dry Eye Syndrome Treatment Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Dry Eye Syndrome Treatment Market Size was estimated at USD 3062.77 million in 2021 and is projected to reach USD 3959.59 million by 2028, exhibiting a CAGR of 3.74% during the forecast period 
Via SBWire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.